<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394481</url>
  </required_header>
  <id_info>
    <org_study_id>2020-000611-74</org_study_id>
    <nct_id>NCT04394481</nct_id>
  </id_info>
  <brief_title>Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery</brief_title>
  <official_title>Extension of the Analgesia of an Interscalene Block of the Brachial Plexus by Combined Injection of Dexamethasone and Dexmedetomidine, After Arthroscopic Shoulder Surgery: Randomized, Controlled, Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GCS Ramsay Santé pour l’Enseignement et la Recherche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EURAXI Pharma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GCS Ramsay Santé pour l’Enseignement et la Recherche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to demonstrate the efficacy of Dexmedetomidine on the
      prolongation of analgesia obtained by interscalenic bloc of the brachial plexus and
      intravenous injection of Dexamethasone (efficacy objective).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, comparative, randomized, controlled study versus reference
      treatment, in 2 parallel groups, double blind (patient and evaluator), multicenter, aiming to
      demonstrate the superiority of This is an interventional, comparative, randomized, controlled
      study versus reference treatment, in 2 parallel groups, double blind (patient and evaluator),
      multicenter, aiming to demonstrate the superiority of Dexmedetomidine over the absence of
      Dexmedetomidine, in adjuvantation of a loco regional anesthesia (interscalenic bloc of the
      brachial plexus + intravenous injection of Dexamethasone), on the prolongation of the
      analgesia, following a surgery of the rotator cuff of the shoulder under arthroscopy.

      Patients will be randomized into 2 groups according to the treatment received:

        -  Dexmedetomidine;

        -  Nothing (control arm). The investigator (anesthesiologist) who will perform the
           randomization will not be blinded to the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of dexmedetomidine in prolonging analgesia</measure>
    <time_frame>96 hours</time_frame>
    <description>Delay between the start of the loco regional anesthésia (H0) and the first post-operative oral morphine intake.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the motor block</measure>
    <time_frame>96 hours</time_frame>
    <description>Delay between H0 and the moment when the patient can move his/her forearm and / or his/her arm again</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the sensitive block</measure>
    <time_frame>96 hours</time_frame>
    <description>Delay between H0 and the moment when the patient claims to have started to experience paraesthesia on his/her shoulder after the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical scale from 0 to 10</measure>
    <time_frame>48 hours</time_frame>
    <description>Pain scores at rest and in motion estimated by the patient at H4, H12, H24 and H48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral opioid analgesics</measure>
    <time_frame>48 hours</time_frame>
    <description>Cumulative amount of oral opioid analgesics taken during the 48 hours post-operative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety analysis</measure>
    <time_frame>96 hours</time_frame>
    <description>Evaluation of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-level Likert scale</measure>
    <time_frame>96 hours</time_frame>
    <description>Patient satisfaction with regard to analgesia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine: 1 µg / kg, reconstituted in 100 mL of physiological saline administered by intravenous during anesthetic induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nothing</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nothing (control arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine injection</intervention_name>
    <description>Auxiliary drug which is administered to all the patients of the study and which contribute to the clinical effect object of the study (prolongation of the locoregional anesthesia)</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_label>Nothing</arm_group_label>
    <other_name>loco regional anesthesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone injection</intervention_name>
    <description>Auxiliary drug which is administered to all the patients of the study and which contribute to the clinical effect object of the study (prolongation of the locoregional anesthesia)</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_label>Nothing</arm_group_label>
    <other_name>loco regional anesthesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years;

          -  Patient undergoing arthroscopic shoulder surgery to repair the rotator cuff tendons;

          -  Patient capable of understanding the information related to the study, of reading the
             information leaflet and agreeing to sign the consent form.

        Exclusion Criteria:

          -  Patient on oral morphines before surgery;

          -  Contraindication to performing a general anesthesia associated with a shoulder loco
             regional anesthesia in a single injection;

          -  Contraindication to take oral morphines;

          -  Any non-arthroscopic repair (intraoperative conversion to &quot;open sky&quot; technique);

          -  Any other loco regional anesthesia than an interscalenic block (change of
             intraoperative strategy);

          -  Pregnant or lactating woman;

          -  Intolerance or allergy or contraindication to one of the treatments under study;

          -  Patient participating in another clinical trial, or in a period of exclusion from
             another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien CABATON</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientific Committee</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien CABATON, MD</last_name>
    <phone>06 16 87 79 19</phone>
    <email>jucabaton@yahoo.fr</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

